Ndrepepa Gjin, Braun Siegmund, Iijima Raisuke, Keta Dritan, Byrne Robert A, Schulz Stefanie, Mehilli Julinda, Schömig Albert, Kastrati Adnan
Deutsches Herzzentrum, Technische Universität, Munich, Germany.
Clin Sci (Lond). 2009 Apr;116(8):651-8. doi: 10.1042/CS20080298.
Although an association between elevated leucocyte count and mortality in patients with ACS (acute coronary syndromes) has been established, the independence of this association from coronary risk factors and C-reactive protein has been inadequately studied. In the present study, this prospective registry included 4329 patients with ACS treated with PCI (percutaneous coronary intervention): 1059 patients with STEMI [ST-segment elevation MI (myocardial infarction)], 1753 patients with NSTEMI (non-STEMI) and 1517 patients with unstable angina. Blood samples were obtained before angiography for leucocyte count and C-reactive protein measurements. The primary outcome of this analysis was 1-year mortality. At 1 year, 345 patients (8%) had died: 45 patients in the 1st tertile, 93 patients in the 2nd tertile and 207 patients in the 3rd tertile of leucocyte count [Kaplan-Meier estimates of mortality, 3.2%, 6.4% and 14.1% with an OR (odds ratio)=2.42, 95% CI (confidence interval)1.78-3.12; P<0.001 for tertile 3 compared with tertile 2 and an OR=1.99, 95% CI 1.77-2.25; P<0.001 for tertile 2 compared with tertile 1]. The Cox proportional hazards model adjusting for coronary risk factors, ACS presentation, extent of coronary artery disease, C-reactive protein and other covariates identified leucocyte count with a HR (hazard ratio)=1.05 (95% CI 1.02-1.07; P<0.001 for 1000 cells/mm(3) increase in the leucocyte count), but not C-reactive protein (HR=1.13, 95% CI 0.95-1.34; P=0.15 for a 1 tertile increase in the C-reactive protein concentration) as an independent correlate of 1-year mortality. We conclude that elevated leucocyte count, but not C-reactive protein, predicts 1-year mortality independent of cardiovascular risk factors across the entire spectrum of patients with ACS treated with PCI.
尽管已证实急性冠状动脉综合征(ACS)患者白细胞计数升高与死亡率之间存在关联,但这种关联独立于冠状动脉危险因素和C反应蛋白的情况尚未得到充分研究。在本研究中,这项前瞻性登记研究纳入了4329例行经皮冠状动脉介入治疗(PCI)的ACS患者:1059例ST段抬高型心肌梗死(STEMI)患者、1753例非ST段抬高型心肌梗死(NSTEMI)患者和1517例不稳定型心绞痛患者。在血管造影术前采集血样以检测白细胞计数和C反应蛋白。该分析的主要结局为1年死亡率。1年时,345例患者(8%)死亡:白细胞计数处于第1个三分位数的患者中有45例,第2个三分位数的患者中有93例,第3个三分位数的患者中有207例[Kaplan-Meier死亡率估计值分别为3.2%、6.4%和14.1%,比值比(OR)=2.42,95%置信区间(CI)1.78 - 3.12;与第2个三分位数相比,第3个三分位数的P<0.001,OR = 1.99,95% CI 1.77 - 2.25;与第1个三分位数相比,第2个三分位数的P<0.001]。经冠状动脉危险因素、ACS表现、冠状动脉疾病范围、C反应蛋白及其他协变量校正的Cox比例风险模型确定,白细胞计数的风险比(HR)=1.05(95% CI 1.02 - 1.07;白细胞计数每增加1000个细胞/mm³,P<0.001),而C反应蛋白不是1年死亡率的独立相关因素(C反应蛋白浓度每增加1个三分位数,HR = 1.13,95% CI 0.95 - 1.34;P = 0.15)。我们得出结论,在接受PCI治疗的整个ACS患者谱中,白细胞计数升高而非C反应蛋白可独立于心血管危险因素预测1年死亡率。